NCT00234871View on ClinicalTrials.gov

Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)

PHASE4CompletedINTERVENTIONAL

Enrollment

357

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2005

Conditions

HypertensionDiabetesProteinuria

Interventions

DRUG

trandolapril/verapamil

2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD

DRUG

Lotrel (amlodipine/benazepril)

5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY

NCT00234871 - Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) | Biotech Hunter | Biotech Hunter